AAIC 2026 findings show a blood test helped primary-care doctors lift diagnostic accuracy from 65% to 93% for symptomatic patients, nearly matching specialists. Patients avoid overreading the headline by treating the test as a clinic-based aid for evaluated memory impairment, not home screening. A blood biomarker test measures blood signals linked to Alzheimer pathology. Here it measured amyloid-beta and p-tau217 ratios alongside history and cognitive testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the Swedish study actually test?
- Why did accuracy rise from 65% to 93%?
- Why is ruling out different from screening?
- What should you do before asking for a test?
What did the Swedish study actually test?
Lund neurologist Sebastian Palmqvist presented a prospective real-world study at AAIC 2026 in London on July 12-15. It enrolled 1,310 cognitively impaired patients evaluated by 165 primary-care and specialist physicians.
The primary-care group included 443 patients, with 257 having mild cognitive impairment and 186 having dementia, at a mean age of 77.8, according to Medscape Medical News Medscape's AAIC report. All patients already had objective impairment and clinical workup.
Why did accuracy rise from 65% to 93%?
Physicians made an initial diagnosis, then saw the C2N PrecivityAD2 result. Healio Neurology reported the test measures amyloid-beta and phosphorylated tau p-tau217 ratios that signal Alzheimer pathology.
Doctors interpreted the result with history and cognitive testing rather than alone. After disclosure, physicians changed the diagnosis in about one-third of patients and changed planned management, further examinations or referrals in more than half to over 60% of cases, according to the Alzheimer's Association release association's conference release.
Why is ruling out different from screening?
The test was strongest for ruling out Alzheimer disease. Medscape Medical News reported primary-care doctors became as accurate as specialists at excluding it, while remaining cautious and referring positive cases for PET or spinal-fluid confirmation.
That performance does not apply to healthy-person screening. The 2025 Alzheimer's Association guideline recommends blood biomarkers only for objectively impaired patients in specialty memory care and requires at least 90% sensitivity and specificity for confirmatory use, as described in the 2025 guideline.
What should you do before asking for a test?
FDA-cleared options include Lumipulse G on May 16, 2025 for symptomatic adults 55 and older and PrecivityAD2 in August-September 2026 for symptomatic adults 40 and older, according to AJMC AJMC approval summary. Both are labeled to complement clinical evaluation, not for unsupervised screening.
- Seek in-person evaluation for persistent memory or thinking changes.
- Ask whether objective impairment is documented by exam or testing.
- Discuss benefits, limits, and whether a positive needs PET or spinal-fluid confirmation.
- Review how results would change referrals, treatment, or follow-up.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Primary Care Patients Can Compare Testing Options
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Primary Care Patients Can Compare Testing Options
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Primary Care Patients Can Compare Testing Options
